Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656370 · ClinicalTrials.gov registry record · Phase 4
Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)
A Phase 4 study, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00656370 is a Phase 4 study that has completed, run by Halozyme Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT00656370, a Phase 4 study, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Randomized, double-blinded study that will evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units. In Stage 1, the comparison will be Normal Saline (NS) solution to Lactated Ringer's (LR) solution. Each subject will receive 500 milliliters (mL) of solution, consisting of NS in one thigh and LR in the other thigh. Immediately prior to the infusions, each thigh will have 150 units of hylenex. In Stage 2, the comparison will be NS solution and buffered NS solution.
Interventions
- DRUG recombinant human hyaluronidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-12 |
| Est. Completion | 2008-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656370
The ClinicalTrials.gov registry entry for NCT00656370 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant human hyaluronidase is the first listed.
NCT00656370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656370 about?
NCT00656370 is a clinical study titled "Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex)". Randomized, double-blinded study that will evaluate the tolerability, safety, and flow rates of different solutions subcutaneously (SC) infused and preceded by human recombinant hyaluronidase (hylenex) 150 units. In Stage 1, the comparison will be Normal Saline (NS) solution to Lactated Ringer's (L...
What is the current status of trial NCT00656370?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2007-12. Estimated completion is 2008-01-30.
What interventions are being tested in trial NCT00656370?
The interventions under investigation include: recombinant human hyaluronidase (DRUG).
Who is sponsoring clinical trial NCT00656370?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.